Anti-hepatitis C virus strategy targeting host entry factor claudin-1

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C virus (HCV) infection is a significant global health concern, linked to severe liver conditions like cirrhosis and hepatocellular carcinoma.
• Host and viral factors are key targets for developing effective anti-HCV preventive and therapeutic interventions.
• HCV entry into hepatocytes involves multiple host factors, including CD81, SRBI, claudin-1, and occludin.

Purpose of the Study:

• To introduce an anti-HCV strategy focused on the host tight junction protein claudin-1.
• To review the development of other HCV entry inhibitors for preventing infection initiation and spread.

Main Methods:

• Targeting host tight junction protein claudin-1 for anti-HCV strategy.
• Summarizing developments in HCV entry inhibitor research.

Main Results:

• Claudin-1 is a viable target for anti-HCV therapeutic strategies.
• Various entry inhibitors have been developed to block HCV infection.
• Entry inhibitors can prevent primary HCV infections and viral spread.

Conclusions:

• Targeting host factors like claudin-1 represents a promising approach for HCV prevention and treatment.
• HCV entry inhibitors may be beneficial in post-transplant settings.
• Combination therapy with entry inhibitors and direct-acting antivirals could enhance treatment efficacy.